Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Biogen Inc.NASDAQ: BIIB
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $236.1M rose 21.5% year over year, ahead of the +13.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 15.5% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.
Context
- Depreciation & amortization amounted to 7.9% of revenue in FY2025, up 1.0 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +21.5% holds above the trailing-twelve-month pace of +13.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 779.9M USD
- Year-over-year change
- +15.8%
- 4-year CAGR
- +12.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 779.9M | +15.8% |
| FY2024 | 2024-12-31 | 673.2M | +36.1% |
| FY2023 | 2023-12-31 | 494.8M | -4.6% |
| FY2022 | 2022-12-31 | 518.4M | +6.3% |
| FY2021 | 2021-12-31 | 487.7M | — |
Depreciation & Amortization vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's LTM Jun 2026 depreciation & amortization of $842.9M is the 5th highest of the 11 companies compared; the peer median is $348.35M.
- Its year-over-year change of +13.2% is the 4th highest of 11, against a peer median of +4.9%.
- Depreciation & amortization amounts to 8.5% of revenue for BIIB, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.58B | -3.0% | +9.2% | 10.3% | |
| LTM Sep 2026 | $6.41B | +29.8% | +3.0% | 10.3% | |
| LTM Jun 2026 | $4.67B | -15.5% | +14.8% | 12.2% | |
| LTM Jun 2026 | $2.1B | +10.9% | +9.5% | 2.6% | |
| LTM Jun 2026 | $842.9M | +13.2% | +14.6% | 8.5% | |
| LTM Jun 2026 | $528.6M | +3.6% | +16.8% | 3.4% | |
| LTM Sep 2026 | $168.1M | -16.2% | +12.3% | 1.3% | |
| LTM Jun 2026 | $91.5M | +14.8% | +18.6% | 2.9% | |
| LTM Jun 2026 | $55.3M | +97.1% | -33.0% | 5.5% | |
| LTM Jun 2026 | $54.76M | -3.1% | +7.8% | 1.1% | |
| LTM Sep 2026 | $21.89M | +6.2% | +0.9% | 2.3% | |
| Peer median (excluding BIIB) | $348.35M | +4.9% | +9.3% | 3.2% | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.98B | 10.17B | 9.84B | 9.68B | 9.81B |
| Cost of Revenue | 2.11B | 2.28B | 2.53B | 2.31B | 2.9B |
| Gross Profit | 8.87B | 7.9B | 7.3B | 7.37B | 6.91B |
| Gross Margin | 80.8% | 77.6% | 74.2% | 76.1% | 70.5% |
| Research & Development | 3.4B | 2.6B | 2.7B | 2.49B | 1.95B |
| Selling, General & Admin | 2.68B | 2.41B | 2.5B | 2.39B | 2.43B |
| Operating Expenses | 6.08B | 5.01B | 5.2B | 4.88B | 5.04B |
| Depreciation & Amortization | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M |
| EBITDA | 3.92B | 3.54B | 2.38B | 3B | 2.95B |
| EBITDA Margin | 35.7% | 34.8% | 24.2% | 31.0% | 30.0% |
| Operating Income | 2.79B | 2.89B | 2.1B | 2.49B | 1.88B |
| Operating Margin | 25.4% | 28.4% | 21.3% | 25.7% | 19.1% |
| Interest Income | 11M | 89.3M | 276.5M | 67.6M | 87.8M |
| Interest Expense | 253.6M | 246.6M | 246.9M | 250.3M | 246M |
| Other Income / Expenses | (1.01B) | 705.3M | (800.5M) | (584.3M) | (476M) |
| Income Before Tax | 1.78B | 3.59B | 1.3B | 1.91B | 1.4B |
| Pre-Tax Margin | 16.2% | 35.3% | 13.2% | 19.7% | 14.3% |
| Income Tax Expense | 52.5M | 632.8M | 135.3M | 273.8M | 108.11M |
| Net Income | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B |
| Net Margin | 14.2% | 29.9% | 11.8% | 16.9% | 13.2% |
| EPS (Basic) | 10.44 | 20.97 | 8.02 | 11.20 | 8.85 |
| EPS (Diluted) | 10.40 | 20.87 | 7.97 | 11.19 | 8.83 |
| Weighted Avg Shares | 149.1M | 145.3M | 144.7M | 145.7M | 146.7M |
| Weighted Avg Shares (Diluted) | 149.6M | 146M | 145.6M | 145.9M | 146.7M |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.